Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;44(10):2151-2161.
doi: 10.1002/hed.27128. Epub 2022 Jun 22.

Presentation and outcomes of patients with clinically T1-2, N0 parotid mucoepidermoid carcinoma: The roles of elective neck dissection and adjuvant radiotherapy

Zaid Al-Qurayshi  1 , Christopher Blake Sullivan  2 , Derek B Allison  3 , Marisa R Buchakjian  1
Affiliations

Presentation and outcomes of patients with clinically T1-2, N0 parotid mucoepidermoid carcinoma: The roles of elective neck dissection and adjuvant radiotherapy

Zaid Al-Qurayshi et al. Head Neck. 2022 Oct.

Abstract

Objectives: Examine the role of elective neck dissection (END) and adjuvant radiotherapy (RT) in early-stage clinically N0 parotid mucoepidermoid carcinoma (MEC).

Methods: The study is a retrospective analysis of the National Cancer Database, 2004-2016. The study population included adult patients with MEC who underwent parotidectomy.

Results: A total of 1233 patients were included. Histopathology demonstrated well, moderately, and poorly differentiated MEC 47.12%, 39.98%, and 12.90% of the time, respectively. END was performed in 78.67% of patients, resulting in nodal upstaging in 4.43% and identification of extracapsular extension (ECE) in 0.72%. RT was utilized in 67.33% of patients with advanced pathological features. Neither END nor RT improved overall survival separately (p < 0.05) or combined (adjusted HR: 1.19, 95%CI: 0.52, 2.70, p = 0.68).

Conclusion: This study provides an epidemiological perspective regarding patients with clinically T1-2, N0 MEC. There was no observed survival advantage with END and RT.

Keywords: epidemiology; facial nerve; mucoepidermoid carcinoma; neck dissection; parotidectomy; radiotherapy; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Figures

FIGURE 1
FIGURE 1
Probability of advanced pathological features in patients with clinically T1‐2, N0 parotid mucoepidermoid carcinoma who underwent surgical resection [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Prevalence of elective neck dissection and positive lymph node(s) in relation to the study period in patients with clinically T1‐2, N0 parotid mucoepidermoid carcinoma who underwent surgical resection [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3
FIGURE 3
Prevalence of adjuvant radiotherapy utilization in relation to the study period and the presence of advanced pathological features (poorly differentiated, T3‐4a, lymphovascular invasion, extracapsular extension, positive surgical margins) in patients with clinically T1‐2, N0 parotid mucoepidermoid carcinoma who underwent surgical resection [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4
FIGURE 4
Overall survival of patients presenting with clinically T1‐2, N0 parotid mucoepidermoid carcinoma based on (A) elective neck dissection outcome, (B) absence or presence of one or more advanced pathological features (poorly differentiated, T3‐4a, positive lymph node(s), positive surgical margins, lymphovascular invasion, extracapsular extension), (C) whether elective neck dissection and adjuvant radiotherapy were utilized in patients with no advanced pathological features, (D) whether elective neck dissection and adjuvant radiotherapy were utilized in patent with one or more advanced pathological features [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Panwar A, Kozel JA, Lydiatt WM. Cancers of major salivary glands. Surg Oncol Clin N Am. 2015;24(3):615‐633. doi:10.1016/j.soc.2015.03.011 - DOI - PubMed
    1. Aro K, Leivo I, Mäkitie AA. Management and outcome of patients with mucoepidermoid carcinoma of major salivary gland origin: a single institution's 30‐year experience. Laryngoscope. 2008;118(2):258‐262. doi:10.1097/MLG.0b013e31815a6b0b - DOI - PubMed
    1. Boahene DKO, Olsen KD, Lewis JE, Pinheiro AD, Pankratz VS, Bagniewski SM. Mucoepidermoid carcinoma of the parotid gland. Arch Otolaryngol Neck Surg. 2004;130(7):849. doi:10.1001/archotol.130.7.849 - DOI - PubMed
    1. Nance MA, Seethala RR, Wang Y, et al. Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer. 2008;113(8):2082‐2089. doi:10.1002/cncr.23825 - DOI - PMC - PubMed
    1. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med. 2009;133(11):1763‐1774. doi:10.1043/1543-2165-133.11.1763 - DOI - PubMed